Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 4:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 85,777 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 1 Clear all
Terminated Phase 1Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer

NCT02607228
View directory record Official record
Conditions
Metastatic Castrate-Resistant Prostate Cancer
Interventions
Alobresib, Enzalutamide
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
4
States / cities
San Francisco, California • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 28, 2026, 4:29 PM EDT
Completed Phase 1 Interventional

A Phase 1b Study of the Safety of REN001 in Patients With Fatty Acid Oxidation Disorders

NCT03833128
View directory record Official record
Conditions
Fatty Acid Oxidation Disorders
Interventions
Low Dose REN001, High Dose REN001
Drug
Lead sponsor
Reneo Pharma Ltd
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
5
States / cities
Aurora, Colorado • Portland, Oregon • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2022 · Synced Oct 28, 2026, 4:29 PM EDT
Active, not recruiting No phase listed Observational

Genomics of Sudden Cardiac Arrest

NCT00661128
View directory record Official record
Conditions
Death, Sudden, Cardiac
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
14,862 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2030
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 28, 2026, 4:29 PM EDT
Completed Phase 1 Interventional Results available

Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma

NCT02215967
View directory record Official record
Conditions
Myeloma, Plasma-Cell, Myeloma-Multiple
Interventions
Cyclophosphamide, Fludarabine, Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 73 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Oct 28, 2026, 4:29 PM EDT
Recruiting Phase 1 Interventional

Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy

NCT05849467
View directory record Official record
Conditions
Progressive Multifocal Leukoencephalopathy, Multiple Sclerosis, Other Neuroinflammatory Diseases With BBB Leakage
Interventions
89 Zr-Df-crefmirlimab
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 28, 2026, 4:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Buprenorphine-Naloxone Sublingual Spray and Suboxone® Sublingual Film in Healthy Volunteers

NCT02477267
View directory record Official record
Conditions
Opiate Dependence
Interventions
SL spray, SL film
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years to 45 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2015 · Synced Oct 28, 2026, 4:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Feasibility Trial of the TELL Tool Intervention

NCT04841967
View directory record Official record
Conditions
Fertility Issues, Disclosure, Parenting
Interventions
TELL Tool Intervention, eBook Attention Control
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
21 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Oct 28, 2026, 4:29 PM EDT
Withdrawn Phase 1 Interventional

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus

NCT06429800
View directory record Official record
Conditions
Lupus Nephritis, Systemic Lupus Erythematosus
Interventions
ATA3219
Drug
Lead sponsor
Atara Biotherapeutics
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Thousand Oaks, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 28, 2026, 4:29 PM EDT
Not listed Phase 1Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer

NCT04813107
View directory record Official record
Conditions
Muscle Invasive Bladder Cancer
Interventions
APL-1202 in combination with tislelizumab, Tislelizumab alone
Drug
Lead sponsor
Jiangsu Yahong Meditech Co., Ltd aka Asieris
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Oct 28, 2026, 4:29 PM EDT
Completed Not applicable Interventional

Increasing Human Papillomavirus Vaccine Uptake in Low-Income, Ethnic Minority Adolescents in Los Angeles County

NCT02067507
View directory record Official record
Conditions
Human Papilloma Virus Infection
Interventions
Tailored education and referral, Staff training and patient reminders, Clinic-level reminder systems
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
9 Years to 70 Years
Enrollment
53,414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Alhambra, California • San Fernando, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2019 · Synced Oct 28, 2026, 4:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Weight Loss Using the Take Shape For Life Program or the Medifast Direct Program Versus a Self-Directed Diet

NCT02835092
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Take Shape For Life Program, Medifast Direct Program, Self-directed Control
Other
Lead sponsor
Medifast, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
198 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Oct 28, 2026, 4:29 PM EDT
Completed Phase 2 Interventional Results available

Pediatrics Testotoxicosis Study [Bicalutamide Anastrozole Treatment for Testotoxicosis]

NCT00094328
View directory record Official record
Conditions
Puberty, Precocious
Interventions
Bicalutamide, Anastrozole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
2 Years to 13 Years · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2017
U.S. locations
9
States / cities
Birmingham, Alabama • Jacksonville, Florida • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Oct 28, 2026, 4:29 PM EDT
Completed Phase 1 Interventional

Dose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF and/or NRAS Mutations

NCT01225536
View directory record Official record
Conditions
Solid Tumor
Interventions
ARQ 736
Drug
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Los Angeles, California • New Haven, Connecticut • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 3, 2013 · Synced Oct 28, 2026, 4:29 PM EDT
Completed Not applicable Interventional Results available

Hair Care Product Use Among Women Of Color

NCT04493892
View directory record Official record
Conditions
Breast Cancer, Pregnancy Related, Exposure During Pregnancy
Interventions
Educational Intervention
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Oct 28, 2026, 4:29 PM EDT
Terminated Phase 1 Interventional

RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma

NCT05557292
View directory record Official record
Conditions
Glioblastoma, Recurrent Glioblastoma
Interventions
RMC-5552
Drug
Lead sponsor
Nicholas Butowski
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 28, 2026, 4:29 PM EDT
Recruiting Not applicable Interventional

The SNAP Tool for Head and Neck Cancer Survivor-Caregiver Dyads

NCT05811936
View directory record Official record
Conditions
Head and Neck Cancer, Survivorship, Caregiver Burden, Head and Neck Neoplasms
Interventions
Survivorship Needs Assessment Planning (SNAP) tool
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 28, 2026, 4:29 PM EDT
Terminated Phase 1 Interventional

Riluzole and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

NCT01018836
View directory record Official record
Conditions
Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
riluzole, whole-brain radiation therapy
Drug · Radiation
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 2, 2014 · Synced Oct 28, 2026, 4:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Effect Study on Pharmacodynamic and Bioavailability of Clopidogrel 300/75 mg in Healthy Subjects

NCT01129271
View directory record Official record
Conditions
Healthy
Interventions
clopidogrel, Matching placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 15, 2011 · Synced Oct 28, 2026, 4:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

CSC OnDemand: An Innovative Online Learning Platform for Implementing Coordinated Specialty Care

NCT03465371
View directory record Official record
Conditions
Psychosis
Interventions
CSC OnDemand Training Intervention, InPerson Intervention, Virtual InPerson Intervention
Other
Lead sponsor
Center for Social Innovation, Massachusetts
Other
Eligibility
18 Years and older
Enrollment
349 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Oct 28, 2026, 4:29 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of EXPAREL® Administered Via a Single Intrathecal Injection to Healthy Volunteers

NCT04173611
View directory record Official record
Conditions
Healthy
Interventions
EXPAREL, Bupivacaine Hydrochloride, Placebo
Drug · Other
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Oct 28, 2026, 4:29 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Opioid Modulation and Neural Reward Activation in Healthy Adults

NCT04854551
View directory record Official record
Conditions
Alcohol Drinking, Opioid Use, Unspecified
Interventions
Naltrexone, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 35 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 28, 2026, 4:29 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Evaluation of Viloxazine and Its Metabolite 5-Hydroxy-viloxazine Glucuronide Into Breast Milk in Healthy Lactating Women

NCT06259331
View directory record Official record
Conditions
Healthy Lactating Women
Interventions
SPN-812 (600mg, QD)
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Oct 28, 2026, 4:29 PM EDT
Withdrawn Phase 2 Interventional

Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney Disease

NCT06598631
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Volenrelaxin, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
16
States / cities
Downey, California • Evergreen Park, Illinois • Hinsdale, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 28, 2026, 4:29 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma.

NCT01416831
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Radiation therapy and high-dose IL-2, High-dose IL-2
Other · Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 28, 2026, 4:29 PM EDT